IP Verse

Compositions And Methods For Treating Ophthalmic Disorders - EP2374472

The patent EP2374472 was granted to Dyax on Jun 12, 2019. The application was originally filed on Mar 13, 2007 under application number EP11152204A. The patent is currently recorded with a legal status of "Revoked".

EP2374472

DYAX
Application Number
EP11152204A
Filing Date
Mar 13, 2007
Status
Revoked
Aug 13, 2021
Publication Date
Jun 12, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BICYCLETXFeb 1, 2019GIBSONADMISSIBLE
LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBBFeb 1, 2019LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBBADMISSIBLE
OXURIONJan 28, 2019GEVERS PATENTSADMISSIBLE

Patent Citations (43) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0171496
DESCRIPTIONEP0173494
DESCRIPTIONEP0184187
DESCRIPTIONGB2007091
DESCRIPTIONUS4079038
DESCRIPTIONUS4093709
DESCRIPTIONUS4131648
DESCRIPTIONUS4138344
DESCRIPTIONUS4180646
DESCRIPTIONUS4271143
DESCRIPTIONUS4304767
DESCRIPTIONUS4407792
DESCRIPTIONUS4615697
DESCRIPTIONUS4816567
DESCRIPTIONUS4946931
DESCRIPTIONUS5041434
DESCRIPTIONUS5786328
DESCRIPTIONUS5968543
DESCRIPTIONUS6010880
DESCRIPTIONUS6057287
DESCRIPTIONUS6087473
DESCRIPTIONUS6333402
DESCRIPTIONUS6413536
DESCRIPTIONUS6596296
DESCRIPTIONUS6613355
DESCRIPTIONUS6667371
DESCRIPTIONWO8601533
EXAMINATIONUS6057287
OPPOSITIONEP1736465
OPPOSITIONUS2004038893
OPPOSITIONUS2005164928
OPPOSITIONUS5187153
OPPOSITIONUS5786328
OPPOSITIONUS5994125
OPPOSITIONUS6989369
OPPOSITIONWO2005095327
OPPOSITIONWO2006091459
OPPOSITIONWO2008016883
SEARCHUS2004171794
SEARCHUS5994125
SEARCHUS6174859
SEARCHWO03103475
SEARCHWO9521601

Non-Patent Literature (NPL) Citations (37) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- BHOOLA ET AL., PHARMACOLOGICAL REVIEWS, (1992), vol. 44, pages 1 - 80
DESCRIPTION- ENGLES, AM J HEALTH SYST PHARM., (2005), vol. 62, pages 9 - 14
DESCRIPTION- GALLIMORE ET AL., THROMB RES, (1979), vol. 16, pages 695 - 703
DESCRIPTION- KONDO ET AL., ENDOCRINOL JPN., (1984), vol. 31, pages 635 - 643
DESCRIPTION- LASKOWSKI; KATO, ANN. REV. BIOCHEM., (1980), vol. 49, pages 593 - 626
DESCRIPTION- LEY ET AL., MOL DIVERS, (1996), vol. 2, pages 119 - 124
DESCRIPTION- MARKLAND ET AL., BIOCHEMISTRY, (1996), vol. 35, pages 8058 - 8067
DESCRIPTION- PETERSEN ET AL., EUR. J. BIOCHEM., (1996), vol. 125, pages 310 - 316
DESCRIPTION- ROBERTS ET AL., CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, (1995), vol. 5, pages 385 - 436
DESCRIPTION- WAGNER ET AL., BIOCHEM. BIOPHYS. RES. COMM., (1992), vol. 186, pages 1138 - 1145
DESCRIPTION- ZHANG ET AL., MED CHEM., (2006), vol. 2, pages 545 - 553
OPPOSITION- BECK et al., "SUBCUTANEOUS ADMINISTRATION OF ECALLANTIDE (DX-88)IN HEREDITARY ANGIOEDEMA: PHARMACOKINETICS,SAFETY, AND PRELIMINARY THERAPEUTIC EXPERIBNCE.", Annals of Allergy, Asthma & Immunology, (20060100), vol. 96, page 136, XP055562949
OPPOSITION- B. Schmidt, "Uberlegungen zur Therapie des Netzhautvenenverschlusses mit Enzyminhibitoren", Klinische Monatsblätter fur Augenheilkunde, (19710000), vol. 158, pages 273 - 277, XP055558891
OPPOSITION- KEDZIERSKA et al., "Plasma Prekallikrein as a Risk Factor for Diabetic Retinopathy", Arch Med Res, (20050000), vol. 36, pages 539 - 543, XP005024640
OPPOSITION- "Recommended INN: List 55", WHO Drug Information, (20060110), vol. 20, no. 1, page 41, XP055562954
OPPOSITION- SCHMIDT, "Uberlegungen zur Therapie des Netzhautvenenverschlusses mit Enzyminhibitoren", Klin Monbl Augenheilk, (19710200), vol. 158, pages 273 - 277, XP055558891
OPPOSITION- DOTSENKO et al., "Hageman factor and kallikrein in pathogenesis of senile cataracts and the pseudoexfoliation syndrome", Immunopharmacology, (19960000), vol. 32, no. 1-3, pages 141 - 145, XP055378942
OPPOSITION- HAN LEE et al., "Approaches toward reversal of increased vascular permeability in C1 inhibitor deficient mice", Immunol. Letters, (20030705), vol. 89, no. 2-3, pages 155 - 160, XP007920919
OPPOSITION- WILLIAMS et al., "DX-88 and HAE: a developmental perspective", Transfusion and Apheresis Science, (20030910), vol. 29, no. 3, pages 255 - 258, XP002605070
OPPOSITION- GAO et al., "Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation", Nature, (20070128), vol. 13, pages 181 - 188, XP055379028
OPPOSITION- GAO et al., "Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation", Nature Med, (20070000), vol. 13, pages 181 - 188, XP055379028
OPPOSITION- KUKNER et al., "Effects of intraperitoneal vitamin E, melatonin and aprotinin on leptin expression in the guinea pig eye during experimental uveitis", Acta Ophthalmol Scand, (20051208), vol. 84, no. 1, pages 54 - 61, XP055378944
OPPOSITION- KÃœKNER et al., "Effects of intraperitoneal vitamin E, melatonin and aprotinin on leptin expression in the guinea pig eye during experimental uveitis", Acta Ophthalmol Scand, (20060000), vol. 84, pages 54 - 61, XP055378944
OPPOSITION- KÃœKNER et al., "Effects of intraperitoneal vitamin E, melatonin and aprotinin on leptin expression in the guinea pig eye during experimental uveitis", Acta Ophthalmol. Scand., (20061208), vol. 84, no. 1, pages 54 - 61, XP055378944
OPPOSITION- XU et al., "Tissue Factor Pathway Inhibitor-2 Is Upregulated by Vascular Endothelial Growth Factor and Suppresses Growth Factor-Induced Proliferation of Endothelial Cells", Arterioscler. Thromb. Vasc. Biol., (20061201), vol. 26, no. 12, pages 2819 - 2825, XP055378935
OPPOSITION- YILMAZ et al., "Aprotinin reduces ischemia-reperfusion injury in the retina of guinea pigs", Eur J Ophthalmol, (20030000), vol. 13, pages 642 - 647, XP055379029
OPPOSITION- YILMAZ et al., "Aprotinin reduces ischemia-reperfusion injury in the retina of guinea pigs", Eur J Ophthalmol, (20030800), vol. 13, pages 642 - 647, XP055379029
OPPOSITION- MAEDA et al., "THE STRUCTURE AND ACTIVITY OF LEUPEPTINS AND RELATED ANALOGS", J. Antibiot., (19710600), vol. 24, no. 6, pages 402 - 404, XP055379046
SEARCH[ ] - CURRENT EYE RESEARCH NOV 1996, (199611), vol. 15, no. 11, ISSN 0271-3683, pages 1117 - 1123
SEARCH- DOTSENKO VERA ET AL, "Hageman factor and kallikrein in pathogenesis of senile cataracts and the pseudoexfoliation syndrome", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (1996), Database accession no. PREV199699088025, XP002476958 [Y] 1-16 * abstract *
SEARCH[ ] - IMMUNOPHARMACOLOGY, (1996), vol. 32, no. 1-3, ISSN 0162-3109, pages 141 - 145
SEARCH- MA J X ET AL, "Kallistatin in human ocular tissues: reduced levels in vitreous fluids from patients with diabetic retinopathy.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (199611), Database accession no. NLM8950506, XP002476957 [Y] 1-16 * abstract *
SEARCH- MA J-X ET AL, "TREATMENT OF RETINAL EDEMA USING PEPTIDE ANGIOGENIC INHIBITORS", BIOSIS, (2003), XP002330417 [X] 1-3,9,14,15 * the whole document * [Y] 4-8 [I] 10-13
SEARCH- MA ET AL, "Expression and cellular localization of the kallikrein-kinin system in ocular tissues", EXPERIMENTAL EYE RESEARCH, ACADEMIC PRESS LTD., LONDON, GB, (1996), vol. 63, ISSN 0014-4835, pages 19 - 26, XP002112528 [Y] 1-16 * the whole document *
SEARCH- GAO G ET AL, "Kallikrein-binding Protein Inhibits Retinal Neovascularization and Decreases Vascular Leakage", DIABETOLOGIA, SPRINGER, BERLIN, DE, vol. 46, no. 5, doi:10.1007/S00125-003-1085-9, ISSN 0012-186X, (20030501), pages 689 - 698, (20040219), XP008122173 [X] 1-3,9,14-16 * the whole document * [Y] 4-8 [I] 10-13
SEARCH- DEVANI ET AL, "Kallikrein-kinin system in inflammatory bowel diseases: Intestinal involvement and correlation with the degree of tissue inflammation", DIGESTIVE AND LIVER DISEASE, W.B. SAUNDERS, GB, (20050901), vol. 37, no. 9, doi:10.1016/J.DLD.2005.01.021, ISSN 1590-8658, pages 665 - 673, XP005012687 [Y] 1-14 * the whole document *
SEARCH- DENNIS MARK S ET AL, "Potent and Selective Kunitz Domain Inhibitors of Plasma Kallikrein Designed by Phage Display", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, (1995), vol. 270, no. 43, ISSN 0021-9258, pages 25411 - 25417, XP002453532 [Y] 1-16 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents